Patents Assigned to Zymed
-
Patent number: 12110532Abstract: The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least about 7500 Daltons. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.Type: GrantFiled: February 16, 2023Date of Patent: October 8, 2024Assignee: DESIGN- ZYME LLCInventors: Peter Albert Petillo, Dwight O'Dell Deay, III
-
Publication number: 20230203557Abstract: The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least about 7500 Daltons. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.Type: ApplicationFiled: February 16, 2023Publication date: June 29, 2023Applicant: Design-Zyme LLCInventors: Peter Albert Petillo, Dwight O'Dell Deay, III
-
Patent number: 11643676Abstract: The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least about 7500 Daltons. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.Type: GrantFiled: April 8, 2021Date of Patent: May 9, 2023Assignee: Design-Zyme LLCInventors: Peter Albert Petillo, Dwight O'Dell Deay, III, Michael Gregory Branden
-
Publication number: 20210230661Abstract: The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least about 7500 Daltons. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.Type: ApplicationFiled: April 8, 2021Publication date: July 29, 2021Applicant: Design-Zyme LLCInventors: Peter Albert Petillo, Dwight O'Dell Deay, III, Michael Gregory Branden
-
Publication number: 20190185900Abstract: The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least about 7500 Daltons. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.Type: ApplicationFiled: December 19, 2018Publication date: June 20, 2019Applicant: Design-Zyme LLCInventors: Peter Albert Petillo, Dwight O'Dell Deay, III, Michael Gregory Branden
-
Patent number: 9260680Abstract: A process for the preparation of a beverage, a beverage base, a beverage concentrate or a beverage additive having a reduced prolamin content from prolamin-containing raw materials, comprising the following steps: a) contacting the beverage or a precursor of the beverage with cross-linking enzymes to obtain modified prolamin; b) removing the modified prolamin at least partially.Type: GrantFiled: November 10, 2005Date of Patent: February 16, 2016Assignee: N-Zyme Biotech GmbHInventors: Ralf Pasternack, Stefan Marx, Dominik Jordan
-
Patent number: 9090870Abstract: Polypeptide with an amino acid sequence according to SEQ ID No. 1 or a variant in which up to 10% of the amino acids have been altered by insertions, deletions or substitution.Type: GrantFiled: November 24, 2009Date of Patent: July 28, 2015Assignee: N-ZYME BIOTEC GMBHInventors: Holger Zorn, Marco Alexander Fraatz, Stephanie Johanna Luise Reimer, Meike Takenberg, Ulrich Krings, Ralf Günter Berger, Stefan Marx
-
Patent number: 8370191Abstract: A method of generating a quantitative indicator of sales for a market segment for a predetermined time period is disclosed. The market segment represents a plurality of members with one or more products. The method includes receiving sales data from the plurality of members of the market segment, calculating the quantitative indicator for each member of the market segment, calculating the quantitative indicator for the market segment by creating a composite of the quantitative indicator for each member representing the market segment, and either calculating the quantitative indicator for the member with missing data using a estimated value of units of the product sold by the member or modifying the baseline benchmark by removing the data of the member with missing data.Type: GrantFiled: January 13, 2010Date of Patent: February 5, 2013Assignee: Zyme Solutions, Inc.Inventors: Chandran Sankaran, Chad Gray, Craig Doud
-
Patent number: 8198063Abstract: The present invention provides methods for rapid deglycosylation of glycoproteins.Type: GrantFiled: September 12, 2007Date of Patent: June 12, 2012Assignee: Pro Zyme, IncInventors: Tomasz Baginski, Thomas G. Warner
-
Publication number: 20120045806Abstract: Polypeptide with an amino acid sequence according to SEQ ID No. 1 or a variant in which up to 10% of the amino acids have been altered by insertions, deletions or substitution.Type: ApplicationFiled: November 24, 2009Publication date: February 23, 2012Applicant: N-ZYME BIOTEC GMBHInventors: Holger Zorn, Marco Alexander Fraatz, Stephanie Johanna Luise Reimer, Meike Takenberg, Ulrich Krings, Ralf Günter Berger, Stefan Marx
-
Publication number: 20100275380Abstract: Process for the tanning of hides and skins, characterized in that hides and skins are treated with tanning agents containing deglycosylated iridoids and/or deglycosylated secoiridoids, excluding tanning agents containing genipin.Type: ApplicationFiled: November 21, 2008Publication date: November 4, 2010Applicant: N-Zyme Biotec GmbhInventors: Jens Zotzel, Stefan Marx, Heinz-Peter Germann, Alla Sarafeddinov
-
Publication number: 20100080785Abstract: The present invention provides novel formulations with improved bioavailability for substances such as ubiquinone, ubiquinol and omega-3 fatty acid. The present invention provides methods and compositions for drying formulations of such substances, wherein those dried formulations can readily be dissolved in water. The compositions and methods of the invention are of particular use in adding nutrients, such as vitamins and minerals, to food products such as beverages.Type: ApplicationFiled: April 8, 2009Publication date: April 1, 2010Applicant: Zymes, LLCInventor: Volker Berl
-
Publication number: 20080254188Abstract: This invention provides aqueous and non-aqueous clear formulations including at least one lipophilic bioactive molecules and an amphiphilic solubilizing agent. Exemplary aqueous formulations include a water-soluble reducing agent, which diminishes or prevents chemical degradation of the lipophilic bioactive molecule. The invention also provides methods of using the formulations of the invention. For example, the invention provides beverages including the formulations of the invention. The invention further provides methods of making the formulations and beverages.Type: ApplicationFiled: February 1, 2008Publication date: October 16, 2008Applicants: National Research Council of Canada, Zymes, LLCInventors: Henryk Borowy-Borowski, Volker Berl
-
Publication number: 20080160077Abstract: This invention relates to an improved formulation methodology for bioactive lipophilic molecules, such as Coenzyme Q10 (CoQ10) and its reduced analogs (ubiquinols). Further provided are methods of producing soft gel capsules of this formulation.Type: ApplicationFiled: November 27, 2007Publication date: July 3, 2008Applicant: Zymes, LLCInventor: Henryk Borowy-Borowski
-
Publication number: 20060251690Abstract: The present invention provides several skin enrichment formulations comprising ubiquinones. The present invention provides a composition for the treatment of acne, topical antimicrobial ointment, sunscreening agents, facial cleansing, reduction of skin inflammation, firming skin tone, cosmetic foundation, skin protection, lip skin protection and skin cream. In a preferred embodiment, the composition contains Coenzyme Q10.Type: ApplicationFiled: April 3, 2006Publication date: November 9, 2006Applicant: Zymes, LLCInventors: Bruce Lipshutz, Deanne Dolnick
-
Patent number: 7129069Abstract: The present invention relates to a hybrid enzyme comprising at least one carbohydrate-binding module amino acid sequence and at least the catalytic module of a glucoamylase amino acid sequence. The invention also relates to the use of the hybrid enzyme in starch processing and especially ethanol production.Type: GrantFiled: October 27, 2004Date of Patent: October 31, 2006Assignees: Novo Zymes Als, Novo Zymes North America, IncInventors: Torben V. Borchert, Steffen Danielsen, Eric J. Allain
-
Publication number: 20060167289Abstract: The present invention provides a convergent method for the synthesis of ubiquinones and ubiquinone analogues. Also provided are precursors of ubiquinones and their analogues that are useful in the methods of the invention. The invention further provides an improved method for the carboalumination of alkyne substrates.Type: ApplicationFiled: December 15, 2005Publication date: July 27, 2006Applicant: Zymes, LLCInventors: Bruce Lipshutz, Volker Berl, Karin Schein, Frank Wetterich
-
Publication number: 20060058283Abstract: The present invention provides antihyperlipidemic or antihypercholesterolemic compositions. These compositions ameliorate the adverse effects associated with other antihyperlipidemic or antihypercholesterolemic compositions. The present invention further provides methods of using the antihyperlipidemic or antihypercholesterolemic compositions.Type: ApplicationFiled: October 25, 2004Publication date: March 16, 2006Applicant: Zymes, Inc.Inventor: Bruce Lipshutz
-
Patent number: 6942970Abstract: The present invention provides methods for diagnosing and treating cancer, and in particular methods for determining the susceptibility of subjects suspected of having breast cancer (or known to have breast cancer) to treatment with topoisomerase II inhibitors. The present invention also provides in situ hybridization probes for specifically detecting topoII? gene sequences.Type: GrantFiled: September 14, 2001Date of Patent: September 13, 2005Assignee: Zymed Laboratories, Inc.Inventors: Jorma Isola, Minna Tanner, Tero Jarvinen, Zuo-Rong Shi, Rina Wu
-
Publication number: 20050148675Abstract: The present invention provides a convergent method for the synthesis of ubiquinones and ubiquinone analogues. Also provided are precursors of ubiquinones and their analogues that are useful in the methods of the invention. The invention further provides an improved method for the carboalumination of alkyne substrates.Type: ApplicationFiled: December 3, 2004Publication date: July 7, 2005Applicant: Zymes, Inc.Inventors: Bruce Lipshutz, Volker Berl, Karin Schein, Frank Wetterich